Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Xbrane Biopharma AB (publ) (XBRANE.ST)
Solna, SE
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibizumab biosimilar presently undergoing pivotal Phase III clinical trials. This therapeutic candidate is being evaluated for the treatment of several serious eye conditions, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. In its earlier, preclinical stages, Xbrane is progressing a range of biosimilars: Xcimzane: Targeting autoimmune diseases such as rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, psoriasis, and Crohn's disease. Xoncane: Designed for acute lymphocytic leukemia. Spherotide: Intended for prostate cancer, breast cancer, endometriosis, and uterine myoma. Xdivane: Developed for various cancers, including melanoma, lung cancer, head and throat cancer, bladder cancer, urinary tract cancer, and renal cell carcinoma. Moreover, Xbrane has established a strategic partnership with STADA Arzneimittel AG. This collaboration aims to explore and potentially pursue joint development and commercialization opportunities for its preclinical biosimilar candidates, Xcimzane and Xdivane.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.58% | +11.23% | +33.59% | +4.79% | +4.17% | +1.25% | -68.54% | -99.90% | -99.93% | -99.76% | -99.75% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-23.3% Q1'26: -81.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+100.3% ★ Q1'26: -195.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-186.5% Q1'26: -49.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-20.4% Q1'26: -61.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-5.8% ★ Q1'26: -7.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+15,365.1% Q1'26: +68.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-3.53× Q1'26: -1.79× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.49M
est: 2.21M (+12.8%)
|
20.77M
est: 24.00M (-13.5%)
|
112.95M
est: 25.08M (+350.3%)
|
57.62M
est: 70.28M (-18.0%)
|
238.73M
est: 191.89M (+24.4%)
|
198.70M
est: 299.30M (-33.6%)
|
152.35M
est: 133.85M (+13.8%)
|
183.00M
183.00M – 183.00M
+36.7% YoY
|
216.00M
216.00M – 216.00M
+18.0% YoY
|
319.00M
319.00M – 319.00M
+47.7% YoY
|
| EBITDA |
-24.53M
est: -2.17M (-1,030.1%)
|
-40.73M
est: -23.60M (-72.6%)
|
-7.05M
est: -24.66M (+71.4%)
|
-149.35M
est: -69.10M (-116.1%)
|
-282.03M
est: -154.43M (-82.6%)
|
-181.97M
est: -240.88M (+24.5%)
|
-16.50M
est: -107.72M (+84.7%)
|
-147.28M
-147.28M – -147.28M
-36.7% YoY
|
-173.84M
-173.84M – -173.84M
-18.0% YoY
|
-256.74M
-256.74M – -256.74M
-47.7% YoY
|
| EBIT |
-27.56M
est: -2.21M (-1,148.4%)
|
-44.81M
est: -24.00M (-86.7%)
|
-11.37M
est: -25.08M (+54.7%)
|
-165.92M
est: -70.28M (-136.1%)
|
-303.53M
est: -161.34M (-88.1%)
|
-217.92M
est: -251.66M (+13.4%)
|
-31.10M
est: -112.54M (+72.4%)
|
-153.87M
-153.87M – -153.87M
-36.7% YoY
|
-181.62M
-181.62M – -181.62M
-18.0% YoY
|
-268.22M
-268.22M – -268.22M
-47.7% YoY
|
| Net Income |
-33.29M
est: -713.86M (+95.3%)
|
-44.94M
est: -475.91M (+90.6%)
|
-13.24M
est: 225.40M (-105.9%)
|
-172.23M
est: -783.12M (+78.0%)
|
-388.17M
est: -1.08B (+64.2%)
|
-266.22M
est: -13.32B (+98.0%)
|
127.24M
est: 22.83B (-99.4%)
|
-2.95B
-2.95B – -2.95B
-112.9% YoY
|
-15.22M
-15.22M – -15.22M
+99.5% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
1.57M
est: 3.63M (-56.6%)
|
12.95M
est: 39.42M (-67.2%)
|
24.28M
est: 41.19M (-41.1%)
|
31.54M
est: 115.42M (-72.7%)
|
40.03M
est: 147.02M (-72.8%)
|
40.11M
est: 229.32M (-82.5%)
|
29.22M
est: 102.55M (-71.5%)
|
140.21M
140.21M – 140.21M
+36.7% YoY
|
165.49M
165.49M – 165.49M
+18.0% YoY
|
244.41M
244.41M – 244.41M
+47.7% YoY
|
| EPS |
-95.00
est: -72.55 (-31.0%)
|
-111.25
est: -48.36 (-130.0%)
|
-28.75
est: 22.91 (-225.5%)
|
-96.25
est: -79.58 (-20.9%)
|
-158.75
est: -0.71 (-22,173.5%)
|
-27.50
est: -8.75 (-214.3%)
|
0.08
est: 15.00 (-99.4%)
|
-1.94
-1.94 – -1.94
-112.9% YoY
|
-0.01
-0.01 – -0.01
+99.5% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Martin Amark | Chief Executive Officer | 4M | male |
| Siavash Bashiri | Chief Operating Officer, Head of Biosimilars & Deputy Chief Executive Officer | 2M | male |
| Bjorn Lager | Head of Quality Assurance | — | male |
| Håkan Yildirim | Head of Intellectual Property | — | male |
| Anders Wallstrom | Head of Technical Operations | — | male |
| Samuel Wagner | Co-Founder & Member of Scientific Advisory Board | — | — |
| Jane Benyamin | Interim Chief Financial Officer & Head of IR | — | female |
| Associate Jan-Willem De Gier | Co-Founder | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XBRANE.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
